Aims: Naltrexone can be used to treat opioid dependence, but patients refuse to take it. Extended-release depot formulations may improve adherence, but long-term adherence rates to depot naltrexone are not known. This study determined long-term rates of adherence to depot naltrexone and whether employment-based reinforcement can improve adherence.
Design: Participants who were inducted onto oral naltrexone were assigned randomly to contingency (n = 18) or prescription (n = 17) groups. Participants were offered six depot naltrexone injections and invited to work at the therapeutic workplace on week days for 26 weeks, where they earned stipends for participating in job skills training. Contingency participants were required to accept naltrexone injections to maintain workplace access and to maintain maximum pay. Prescription participants could work independently of whether they accepted injections.
Setting: The therapeutic workplace, a model employment-based intervention for drug addiction and unemployment.
Participants: Opioid-dependent unemployed adults.
Measurements: Depot naltrexone injections accepted and opiate-negative urine samples.
Findings: Contingency participants accepted significantly more naltrexone injections than prescription participants (81% versus 42%), and were more likely to accept all injections (66% versus 35%). At monthly assessments (with missing urine samples imputed as positive), the groups provided similar percentages of samples negative for opiates (74% versus 62%) and for cocaine (56% versus 54%). Opiate-positive samples were more likely when samples were also positive for cocaine.
Conclusions: Employment-based reinforcement can maintain adherence to depot naltrexone. Future research should determine whether persistent cocaine use compromises naltrexone's effect on opiate use. Workplaces may be useful for promoting sustained adherence to depot naltrexone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107896 | PMC |
| http://dx.doi.org/10.1111/j.1360-0443.2011.03400.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable Cross-Linked Depots.
bioRxiv
August 2024
Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Achieving ultra-long-term release of hydrophilic drugs (over six months) poses a challenge for existing long-acting injectables (LAIs), which often face issues like burst release and rapid drug diffusion due to their design.
- A new injectable platform called ISCD, created using a methacrylated ultra-low molecular weight pre-polymer (polycaprolactone), addresses these issues by minimizing burst release and controlling water exchange through a dense mesh network.
- Studies show that ISCD successfully delivers various hydrophilic drugs (including antiretrovirals and antibiotics) and enables co-delivery of multiple drugs, with the potential for improved adherence in chronic conditions while surpassing the one-month drug release standard of existing LA
Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
J Gen Intern Med
June 2024
Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
Background: Treatment-seeking people with opioid use disorder (OUD) who are capable of pregnancy need accurate information about the potential impact of medication to treat OUD (MOUD) on fertility to make informed choices about treatment that are consistent with their reproductive wishes. There is a dearth of research on fertility associated with MOUD receipt in birthing people with OUD.
Objective: To estimate the association between treatment with MOUD and odds of conception among birthing people using national administrative claims.
Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report.
J Addict Med
March 2024
From the Penn Medicine, University of Pennsylvania, Philadelphia, PA (JB, EC); University of Pennsylvania School of Nursing, Philadelphia, PA (JB); Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (RS, JC).
Introduction: Buprenorphine extended-release subcutaneous injection (BUP-XR) is a medication used to treat opioid use disorder. It is a long-acting formulation of buprenorphine, which is a partial opioid agonist. Buprenorphine extended-release subcutaneous injection is injected into the subcutaneous space forming a depot that can last up to a month.
View Article and Find Full Text PDFThermosensitive biomaterial gels with chemical permeation enhancers for enhanced microneedle delivery of naltrexone for managing opioid and alcohol dependency.
Biomater Sci
August 2023
Department of Pharmaceutical Sciences and Experimental Therapeutics, The University of Iowa College of Pharmacy, Iowa City, IA 52242, USA.
Naltrexone (NTX) can be transdermally delivered using microneedles (MN) to treat opioid and alcohol misuse disorders, but delivery is blunted by rapid micropore closure. Poloxamer (P407), a thermosensitive biocompatible hydrogel, sustains NTX delivery through MN-treated skin by generating a drug depot within the micropores. Optimizing P407 formulations could maintain sustained delivery after micropore closure while reducing required patch sizes, which would be more discreet and preferred by most patients.
View Article and Find Full Text PDFExperience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
BMJ Open
October 2022
Addictions Department, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Introduction: Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injectable buprenorphine (BUP-XR) has been developed to enhance treatment effectiveness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!